Press Release: Novartis: Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study

Novartis International AG / Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study. Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. -- 51-week clinical study confirms......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - 7 days ago
Share |